Dr. Reddy's Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges
News Desk, News Nation 360: Dr Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. market. This launch truly demonstrates the ability to deliver on more complex dosage forms for the benefit of consumers who wish to quit smoking by reducing withdrawal symptoms, including nicotine cravings. The Nicotine Lozenges brands and store brand markets had total U.S. retail sales of approximately $200 million for the most recent 52 weeks ending on May 17, 2020, according to IRI. Marc Kikuchi, CEO, North America Generics, Dr Reddy’s Laboratories, told the launch of Nicotine Polacrilex Lozenges represents their continuing commitment to the OTC category of Smoking Cessation. Nicotine Polacrilex Lozenges are an important addition to their current offering of Nicotine Replacement Therapy including Nicotine Transdermal System Patches, sold as Habitrol® brand and various store brands. Dr Reddy’s Nicotine Polacrilex Lozenges are available in multiple pack sizes based on consumers’ requirements.
Report : Anustup Kundu